StoneX Group
DMK

StoneX Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

StoneX Group’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,258
Closed -$9.14K – 761
2023
Q3 		$9.14K Buy
+13,258
New +$17K ﹤0.01% 592

Other funds holding DMK

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Virtu Financial
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Two Sigma Securities
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

StoneX Group's DMK Position: Q4 2023 in Review

StoneX Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2023, closing a stake of 13,258 shares — an estimated $9.14K sold.

StoneX Group first reported a position in DMK in Q3 2023 and held it in 1 quarter. The position peaked at $9.14K in Q3 2023. 29 funds tracked by Wall St. Rank hold DMK as of Q4 2023.

  • StoneX Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2023 after selling out during the quarter.
  • StoneX Group sold 13,258 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2023, an estimated $9.14K.
  • StoneX Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2023 and held it in 1 quarter.
  • StoneX Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $9.14K in Q3 2023.
  • 29 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2023.

Based on StoneX Group's 13F filing for Q4 2023, filed 12 Feb 2024.